Phaseline

Targets › GRIN2C

GRIN2C (Glutamate receptor ionotropic, NMDA 2C): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Psychiatry, Other; next expected readout Sep 2027.

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+). Participates in synaptic plasticity for learning and memory formation by contributing to the slow phase of excitatory postsynaptic current and long-term synaptic potentiation (By similarity). (UniProt, Q14957)

Open in Phaseline: the race on GRIN2C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Syndeio BiosciencesZelquistinel
Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2DPhase 2Major Depressive Disorder; Healthy Volunteers in Fed and Fasted StateSep 2027
The AlfredNMDA receptor antagonist
NMDA receptor antagonist
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2DPhase 2Borderline Personality Disorder–

Conditions

Major Depressive Disorder (2) Borderline Personality Disorder (1) Healthy Volunteers in Fed and Fasted State (1)

Modalities

small molecule (2)

Companies

The Alfred (1) Syndeio Biosciences (1)

Related targets

GRIN1 (2) GRIN2A (2) GRIN2B (2) GRIN2D (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.